Correction: Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

Correction: Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-10-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e000381corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
by: Jian Wang, et al.
Published: (2020-05-01)

Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC
by: Hui Li, et al.
Published: (2024-11-01)

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
by: Mariano Severgnini, et al.
Published: (2020-10-01)

Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors
by: Anakha D. Rajeeve, et al.
Published: (2025-01-01)

Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC
by: Xin Zheng, et al.
Published: (2024-12-01)

TDERS, an exosome RNA-derived signature predicts prognosis and immunotherapeutic response in clear cell renal cell cancer: a multicohort study
by: Aimin Jiang, et al.
Published: (2024-12-01)

Identification of multicohort-based predictive signature for NMIBC recurrence reveals SDCBP as a novel oncogene in bladder cancer
by: Chen Zhang, et al.
Published: (2025-12-01)

Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials
by: Weiming Zhang, et al.
Published: (2024-12-01)

Correction: KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
by: Jinghan Li, et al.
Published: (2025-01-01)

Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures
by: Drew M Pardoll, et al.
Published: (2021-06-01)

Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers
by: Ruihua Fang, et al.
Published: (2025-01-01)

Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
by: Irina Surovtsova, et al.
Published: (2025-12-01)

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
by: Alexander Huang, et al.
Published: (2020-10-01)

Development and validation of a nomogram model based on blood-based genomic mutation signature for predicting the risk of brain metastases in non-small cell lung cancer
by: Jiabin Fang, et al.
Published: (2024-12-01)

Correction: Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
Published: (2020-05-01)

Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
by: Armando Santoro, et al.
Published: (2024-11-01)

Survival outcome prediction of esophageal squamous cell carcinoma patients based on radiomics and mutation signature
by: Ting Yan, et al.
Published: (2025-01-01)

Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC
by: Yun-Ching Chen, et al.
Published: (2024-12-01)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
by: Chiao-En Wu, et al.
Published: (2020-01-01)

Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC
by: Florian Posch, et al.
Published: (2024-04-01)

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
by: Dirk Schadendorf, et al.
Published: (2022-12-01)

Characterization of the genomic landscape in liver oligometastatic NSCLC
by: Rongxin Liao, et al.
Published: (2025-01-01)

Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
by: Madhusudan Roy, et al.
Published: (2024-03-01)

RET mutated non-small cell lung cancer (NSCLC) in association with patients from Central America
by: Lily Z. Chen, et al.
Published: (2024-01-01)

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)
by: Stefania Angelicola, et al.
Published: (2025-01-01)

Mutational Prognosis of Survival by Liquid Biopsy in Advanced EGFRm NSCLC
by: M. Galvez-Nino, et al.
Published: (2023-11-01)

Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay
by: Ticiana Leal, et al.
Published: (2020-05-01)

Multicohort analysis identifies conserved transcriptional interactions between humans and Plasmodium falciparum
by: Bárbara Fernandes Silva, et al.
Published: (2024-12-01)

Genomic Profiling in NSCLC: Insights from Liquid Biopsy
by: C. Ercolani, et al.
Published: (2023-11-01)

Letter to the editor, “Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – Implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy.”
by: Geetha Shanmugam
Published: (2024-09-01)

Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2025-01-01)

Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC
by: Hong Liu, et al.
Published: (2024-12-01)

CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
by: Francois-Xavier Danlos, et al.
Published: (2022-02-01)

Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short Review
by: Zhang C, et al.
Published: (2025-01-01)

Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1
by: Zachary D. Wallen, et al.
Published: (2024-11-01)

Responsive afatinib treatment in high-grade salivary gland ductal carcinoma and NSCLC with uncommon EGFR mutations: Treatment outcomes
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
by: Metin Eser, et al.
Published: (2024-11-01)

Development of diffuse cutaneous squamous cell carcinoma in situ after chemotherapy for ovarian carcinoma and remission with PD1-inhibitor
by: Jess Durbin, et al.
Published: (2024-12-01)

KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
by: Jinghan Li, et al.
Published: (2024-02-01)

Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations
by: Nadia Ghazali, et al.
Published: (2024-12-01)